M701 for lung cancer with pleural effusion
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called M701 for people with non-small cell lung cancer that has spread to the lining of the lung, causing fluid buildup (pleural effusion). It aims to see if M701 can help control the fluid and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have non-small cell lung cancer that has worsened after at least one prior treatment.
- You have a moderate or large amount of fluid around the lung (pleural effusion) that needs to be drained.
- Any side effects from previous cancer treatments have mostly resolved (except for hair loss, skin changes, or mild nerve issues).
- Your overall health is good enough to be up and about (ECOG score 0–1, or 2 if the fluid is not well controlled).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
This trial tests a new combination of two investigational drugs, 7MW3711 and JS207, for people with advanced solid tumors that no longer respond to standard treatments. It aims to see if this combination is safe and effective.
This trial tests a new drug called MT027 for people with advanced cancer that has spread to the lining around the lungs (pleura) and caused fluid buildup. The drug targets a marker on cancer cells called B7-H3. It may help control the fluid and the cancer.
This trial tests an investigational drug called JMKX000197 given into the chest to control fluid buildup caused by cancer. It is for people with advanced solid tumors that have led to a moderate or large pleural effusion requiring drainage.
This study tests a new injectable drug called JMKX000197 compared to cisplatin (a standard chemotherapy) to treat fluid buildup around the lungs caused by advanced cancer. The goal is to see if the new drug works as well as or better than cisplatin with fewer side effects.
This trial tests a new drug given directly into the chest cavity to treat fluid buildup caused by non-small cell lung cancer. It may help ease breathing problems and control the fluid.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.